Risk Factors
424 articles
Neoantigens Provide New Hope for Pancreatic Cancer Treatments
Vinod Balachandran’s team identified increased T cells in the tumors of long-term pancreatic cancer survivors, with a role for neoantigens in immunotherapy.
The Stroma Presents Challenges and Treatment Opportunities
Dr. Elizabeth Jaffee explains how researchers are approaching penetrating the fibrous stroma around pancreatic tumors, which has long challenged treatment.
A Simple Blood Test for Early Detection of Eight Cancers Shows Promise
Dr. Anne Marie Lennon explains the CancerSEEK blood test, a liquid biopsy in clinical trials for early detection of eight cancers, including pancreatic.
Precision Medicine from the Get-Go for Pancreatic Cancer
Dr. Ben George and colleagues at the Medical College of Wisconsin are using molecular profiling to determine the best chemotherapy for a patient’s pancreatic cancer.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
Immunology Researchers Solve a Mystery of Metastasis
Physician and researcher Douglas Fearon and his lab have a possible explanation for how cancer cells metastasize, and the role surgery may play in this process.
Exercise Helps Boost Immune System and Immunotherapy Treatment
Dr. Emma Kurz is part of a research team that has found that exercise can help make immunotherapy more effective for pancreatic cancer.
Adjuvant Chemotherapy with Modified FOLFIRINOX Regimen Improves Survival
A French clinical trial showed that adjuvant chemotherapy (given after surgery) with modified FOLFIRINOX improves survival of pancreatic cancer patients.
New Research Sheds Light on Hot and Cold Tumors
Dr. Ben Z. Stanger and his team are finding links between the number of T cells a tumor has and the effectiveness of immunotherapy.
Tough Tortoise of a Drug Beating Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
Medical Marijuana: More Science Could Help Clear the Air
What’s the scoop on medical marijuana? Legal? Helpful? Find the most up-to-date information on what it is approved for, and where the research is going.
Aiming to Improve Immunotherapy for Pancreatic Cancer
Dr. Deirdre Cohen discusses clinical trials that aim to improve the effectiveness of immunotherapy for pancreatic cancer.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Microbiome May Hold the Key To Better Treatment
Dr. Deirdre Cohen’s research into the pancreatic microbiome has found that gut bacteria may directly influence the effectiveness of immunotherapy.